Biodexa Pharmaceuticals Plc (BDRX)
Score window: May. 30, 2025 to May. 29, 2026
| Date | Form | Sentiment | Urgency | Summary | Open |
|---|---|---|---|---|---|
| Sep. 29, 2025 | CORRESP | Neutral/Informational | Moderate | Biodexa Pharmaceuticals PLC has submitted a request to the SEC for the acceleration of the effective date of their Registration Statement on Form F-3. They are seeking to have the… | Read Filing EDGAR |
| Sep. 29, 2025 | UPLOAD | Neutral/Informational | Low | The SEC correspondence dated September 29, 2025, informs Stephen Stamp, CEO of Biodexa Pharmaceuticals PLC, that the SEC has not reviewed and will not review the company's registr… | Read Filing EDGAR |
| Aug. 20, 2025 | UPLOAD | Neutral/Informational | Low | The SEC has completed its review of Biodexa Pharmaceuticals plc's Form 20-F for the fiscal year ended December 31, 2024. They remind the company and its management of their respon… | Read Filing EDGAR |
| Aug. 19, 2025 | CORRESP | Neutral/Informational | Moderate | Biodexa Pharmaceuticals Plc has submitted a response to the SEC's comment letter regarding their Form 20-F for the fiscal year ended December 31, 2024. The SEC requested more deta… | Read Filing EDGAR |
| Aug. 18, 2025 | UPLOAD | Concern from SEC | High | The SEC has conducted a limited review of Biodexa Pharmaceuticals' Form 20-F for the fiscal year ended December 31, 2024, focusing on financial statements and related disclosures.… | Read Filing EDGAR |